scholarly journals Evaluation of pemetrexed in the treatment of epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer: a retrospective study

2020 ◽  
Author(s):  
Yanmei Wu ◽  
Jie Jiang
Keyword(s):  
Ovarian Cancer ◽  
Side Effects ◽  
Epithelial Ovarian Cancer ◽  
Fallopian Tube ◽  
Progression Free Survival ◽  
Fallopian Tube Cancer ◽  
Peritoneal Cancer ◽  
Platinum Sensitive ◽  
Platinum Resistant ◽  
Pemetrexed Disodium

Abstract Background: The aim of this study was to evaluate the efficacy and safety of pemetrexed in the treatment of epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.Results: Patients with platinum-sensitive and platinum-resistant epithelial ovarian cancer who received pemetrexed disodium chemotherapy at Qilu Hospital of Shandong University between January 2015 and December 2018 were identified. Dose delay and adjustment were permitted when serious side effects occurred. To observe the efficacy rate and follow up on its side effects, progression-free survival and overall survival after chemotherapy were monitored. A total of 96 cases were collected, and 340 cycles of chemotherapy were administered. The overall response rate (ORR) was 32.29% (31 patients), where 16 patients (16.67%) had a complete response, and 15 patients (15.62%) had a partial response. There were 68 platinum-resistant patients and 28 platinum-sensitive patients. The ORRs of platinum-sensitive and platinum-resistant patients were 42.86% (12 patients) and 27.94% (19 patients), respectively, p = 0.16. The median progression-free survival (PFS) was 3.52 months and 2.97 months (HR0.62, 95% CI, 0.37-1.02), respectively, and there was no significant difference (P = 0.06). The median overall survival (OS) of the two groups was 36 months and 18 months, respectively, and the difference was statistically significant (p= 0.01). There was no drug-related death in all patients, and all of the side effects were mild. The most common side effects were myelosuppression, gastrointestinal reactions and hepatotoxicity.Conclusion: Pemetrexed disodium is effective not only for platinum-sensitive but also platinum-resistant epithelial ovarian cancer. And the side effects are tolerable. Pemetrexed disodium may be a choice for epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

scholarly journals Bevacizumab in the Management of Epithelial Ovarian Cancer

2013 ◽  
Vol 09 (02) ◽  
pp. 129
Author(s):  
Maurie Markman ◽  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Cancer Progression ◽  
Single Agent ◽  
Strong Support ◽  
Progression Free Survival ◽  
Optimal Dose ◽  
Phase Iii ◽  
Platinum Sensitive ◽  
Platinum Resistant

Preclinical investigations have provided strong support for the hypothesis that angiogenesis is a potent driver of epithelial ovarian cancer progression. Phase II data have revealed the activity of single-agent bevacizumab in previously treated and clinically defined platinum-resistant ovarian cancer. Several reported phase III randomized trials, involving primary and both ‘platinum-sensitive’ recurrent and platinum-resistant disease, have demonstrated the addition of bevacizumab to a cytotoxic chemotherapy regimen improves progression-free survival compared with chemotherapy alone. While there continues to be considerable debate regarding the optimal dose, timing, and duration of bevacizumab administration in ovarian cancer, the existing data provide strong support for an important role for this agent in the overall management paradigm for this malignancy.

Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 5538-5538 ◽  
Author(s):  
Wendy M Swetzig ◽  
John Robert Lurain ◽  
Emily Berry ◽  
Mario Javier Pineda ◽  
Shohreh Shahabi ◽  
...  
Keyword(s):  
Fallopian Tube ◽  
Kinase Inhibitor ◽  
Progression Free Survival ◽  
Median Number ◽  
Vegf Receptor ◽  
Open Label ◽  
Fallopian Tube Cancer ◽  
Primary Peritoneal Cancer ◽  
Peritoneal Cancer ◽  
Platinum Resistant

5538 Background: Tivozanib is a potent, selective pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor with a long half-life. This study assessed its activity in patients with recurrent, platinum-resistant ovarian cancer (OC), fallopian tube cancer (FTC) or primary peritoneal cancer (PPC). Methods: This open-label phase II study used a Simon’s two-stage design. Eligible patients had recurrent, platinum-resistant OC, FTC or PPC; ECOG PS of 0-1; normal end organ function; and measurable or detectable disease. There was no limit on the number of prior regimens. Treatment consisted of tivozanib 1.5 mg orally once daily (3 weeks on/1 week off). The primary endpoint was response rate. Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity assessment. If 1 partial response (PR) was observed in stage I [n = 12], enrollment proceeded to stage II. The null hypothesis was rejected for ≥ 4 responses in 30 patients. Results: Thirty-one patients were enrolled, and 30 were treated. Twenty-three had OC [76.67%], 5 FTC [16.67%] and 2 PPC [6.67%]. Twenty-six had measurable [86.67%] and 4 detectable disease [13.37%]. The median age was 60, and median number of prior regimens was 4 [range 1-9]. Four PRs [13.33%] were recorded. Twelve patients had stable disease (SD) [40%]. The clinical benefit rate (PR + SD) was 53%. Seven patients [23.33%] survived progression-free for > 6 mos. One patient continued treatment for > 2 yrs. The median PFS was 4 mos [range 1-25] and median OS was 8 mos [range 1-39]. There were no treatment-related deaths. Grade 3-4 related toxicities were hypertension [8], fatigue [3], fistula [2], hyponatremia [2], intestinal perforation, obstruction, stroke, proteinuria, hypomagnesemia, hypoalbuminemia, portal hypertension, nausea and anemia [1 each]. Frequent grade 1-2 related toxicities included fatigue [19], hypertension [13], anorexia [12], arthralgia [11], diarrhea [11], weight loss [10], hoarseness [8], headache [8] and nausea [7]. Exploratory analyses in tumor samples are ongoing. Conclusions: Tivozanib is active in patients with recurrent OC, FTC or PPC, without substantial toxicity, supporting its further development. Clinical trial information: NCT01853644.

Phase II Trial of Irinotecan in Patients With Metastatic Epithelial Ovarian Cancer or Peritoneal Cancer

2003 ◽  
Vol 21 (2) ◽  
pp. 291-297 ◽  
Author(s):  
Diane C. Bodurka ◽  
Charles Levenback ◽  
Judith K. Wolf ◽  
Jacalyn Gano ◽  
J. Taylor Wharton ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Median Survival ◽  
Performance Status ◽  
Progression Free Survival ◽  
Cancer Center ◽  
Primary Peritoneal Cancer ◽  
Peritoneal Cancer ◽  
Platinum Resistant ◽  
Platinum Refractory

Purpose: To evaluate the efficacy and toxicity of irinotecan in patients with metastatic platinum-resistant or platinum-refractory epithelial ovarian cancer or primary peritoneal cancer.Patients and Methods: Thirty-one patients with measurable disease were enrolled in our study at The University of Texas M.D. Anderson Cancer Center. Twenty-five of these patients were treated with irinotecan at a dose of 300 mg/m2intravenously for 90 minutes every 3 weeks; the remaining six patients were treated with 250 mg/m2because their age was greater than 65 years. Median age was 57 years (range, 38 to 74 years). The majority (84%) had a Zubrod performance status of 0. All patients were evaluated for irinotecan toxicity, and 29 (94%) were evaluable for response.Results: The overall response rate was 17.2%. One patient (3%) had a complete response, four (14%) had partial responses, 14 (48%) had stable disease, and 10 had (35%) disease progression. Median progression-free survival was 2.8 months (range, 1.1 to 16 months), median duration of response was 1.4 months (range, 0.7 to 10.1 months); median survival from primary diagnosis was 24.3 months (range, 6.5 to 85.7 months); and median survival from initiation of irinotecan was 10.1 months (range, 2.3 to 34 months). Major toxicities included fatigue (16 patients), neutropenia (11 patients), diarrhea (nine patients), nausea (10 patients), and anorexia (seven patients). Eleven patients required dose reductions because of these toxicities. No treatment-related deaths occurred.Conclusion: Irinotecan has moderate efficacy and substantial toxicity in patients with metastatic platinum-resistant or platinum-refractory epithelial ovarian or primary peritoneal cancer.

Sign in / Sign up

Export Citation Format

Share Document